Disponibili on line nuove e importanti informazioni di sicurezza relative all’utilizzo di
medicinali a base di piperacillina/tazobactam per uso endovenoso.
Product marketed as dietary supplement contains sulfoaildenafil, which may interact with nitrates found in some prescription drugs and lower blood pressure to dangerous levels.
Disponibili on line nuove e importanti informazioni riguardanti il rischio cardiaco in seguito all’utilizzo dei medicinali a base di domperidone.
Disponibili on line nuove ed importanti informazioni di sicurezza sull'associazione di Scintimun (besilesomab) e rischio potenziale di generazione di anticorpi umani antimurini (HAMA), di reazioni di ipersensibilità e di ipotensione acuta.
On October 26, 2011, the Canadian Agency for Drugs and Technologies in Health (CADTH) signed an agreement with the Pan American Health Organization (PAHO), granting PAHO permission to translate the Rx for Change database into Spanish. This agreement will make the unique database available to the Americas and potentially improve the prescribing practice and use of drugs and other health technologies in these regions.
On October 26, 2011, the Canadian Agency for Drugs and Technologies in Health (CADTH) signed an agreement with the Pan American Health Organization (PAHO), granting PAHO permission to translate the Rx for Change database into Spanish. This agreement will make the unique database available to the Americas and potentially improve the prescribing practice and use of drugs and other health technologies in these regions.
Potential for patient falls or unanticipated patient movement, which may result in serious injury or death.
The ACCORD Lipid trial found no significant difference in the risk of a major adverse cardiac event between group treated with fenofibrate plus simvastatin compared with simvastatin alone.
Failure to adequately ventilate may lead to hypoxia or hypercarbia, which may result in serious neurological injury or death.
OTTAWA — The Canadian Agency for Drugs and Technologies in Health (CADTH) today announced the appointment of a Public Member to its recently established Health Technology Expert Review Panel. The Panel is an advisory body, convened to develop guidance and recommendations to CADTH on non-drug health technologies such as medical devices. The Panel consists of Core Members, who are appointed to serve for all topics under consideration, and Expert Members, who are appointed on a per-project basis, providing expertise on specific topics.
80.211.154.110
